Top 10 Penny Stocks with Strong Financials and Growth Trajectories

ProKidney Corp. is a clinical-stage biotech firm focused on treating chronic kidney diseases. The company has a market cap of $604.68 million and is pre-revenue, with less than $1 million in earnings. Despite being debt-free and having an experienced board, ProKidney remains unprofitable and is not expected to achieve profitability within the next three years. Its cash runway extends for over a year under current conditions.